Guided Therapeutics, Inc. (GTHP) Stock Analysis

Guided Therapeutics, Inc. (GTHP) Healthcare & Pipeline Overview

Guided Therapeutics, Inc. is a medical device company specializing in non-invasive cervical cancer detection with its LuViva device. Targeting point-of-care diagnostics, the company operates in a competitive medical device market, facing challenges in commercialization and market adoption within the broader healthcare sector.

What Is the Investment Thesis for GTHP?

Guided Therapeutics, Inc. presents a high-risk, high-reward investment profile. The company's LuViva device targets a critical need for improved cervical cancer screening, offering a potential alternative to traditional methods. However, the company's financial performance, with a negative profit margin of -1478.7% and reliance on OTC markets, raises concerns about its long-term viability. The success of Guided Therapeutics hinges on successful commercialization of LuViva, regulatory approvals, and market adoption. Investors should carefully consider the company's limited resources, competitive landscape, and dependence on future funding to sustain operations. The company's beta of 0.56 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

GTHP Key Highlights

Market capitalization of $24.1M indicates a micro-cap company with limited financial resources.

• Negative P/E ratio of -8.69 reflects the company's current lack of profitability.
• Gross margin of 33.7% suggests potential for profitability if sales volume increases and operating expenses are managed effectively.
• Profit margin of -1478.7% highlights significant losses and the need for improved cost management.
• The company operates with only 4 employees, indicating a lean organizational structure and reliance on external partnerships.

Who Are GTHP's Competitors?

GTHP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GTHP's Key Strengths?

Non-invasive cervical cancer detection.

• Point-of-care diagnostic capability.
• Proprietary LuViva technology.
• Potential for improved patient compliance.

What Are GTHP's Weaknesses?

Limited financial resources.

• Negative profit margin.
• Small number of employees.
• Reliance on OTC markets.

What Could Drive GTHP Stock Higher?

Potential regulatory approvals for LuViva in new geographic regions.

• Strategic partnerships with healthcare providers and distributors.
• Continued commercialization efforts for LuViva in the United States.
• Research and development of new features for the LuViva device.
• Direct-to-consumer marketing campaigns to raise awareness of LuViva.

What Are the Key Risks for GTHP?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Competition from established screening methods and alternative technologies.
• Regulatory hurdles and delays in obtaining approvals.
• Limited financial resources and dependence on future funding.
• Negative profit margin and need for improved cost management.
• Limited market adoption and resistance to new technologies.

What Are the Growth Opportunities for GTHP?

• Market Expansion: Guided Therapeutics has the opportunity to expand its market reach beyond the United States by obtaining regulatory approvals in other countries. The global cervical cancer screening market presents a significant opportunity for growth, particularly in developing countries with limited access to traditional screening methods. Successful international expansion could significantly increase LuViva sales and revenue.
• Strategic Partnerships: Collaborating with established healthcare providers and distributors can accelerate the adoption of LuViva. Partnering with large hospital networks, clinics, and women's health organizations can provide access to a wider patient base and enhance the credibility of the device. Strategic alliances can also facilitate market entry into new geographic regions.
• Product Development: Enhancing the capabilities of the LuViva device through further research and development can improve its accuracy and expand its applications. Developing new features, such as integration with electronic health records or improved data analytics, can increase the value proposition of the device and attract more customers. Continuous innovation is essential to maintain a competitive edge in the medical device industry.
• Direct-to-Consumer Marketing: Implementing a direct-to-consumer marketing strategy can raise awareness of LuViva and drive demand for the device. Educating women about the benefits of non-invasive cervical cancer screening can increase patient interest and encourage them to discuss LuViva with their healthcare providers. Effective marketing campaigns can also help to overcome resistance to new technologies.
• Point-of-Care Diagnostics: Capitalizing on the growing trend towards point-of-care diagnostics can drive adoption of LuViva. Point-of-care testing offers convenience and faster results, which can improve patient compliance and reduce the time to diagnosis. As healthcare systems increasingly prioritize efficiency and patient-centered care, the demand for point-of-care diagnostic solutions is expected to grow.

What Are GTHP's Competitive Advantages?

• Proprietary LuViva technology.
• Non-invasive cervical cancer detection method.
• Point-of-care diagnostic capability.
• Potential for improved patient compliance.

What Does GTHP Do?

Guided Therapeutics, Inc., originally incorporated as SpectRx, Inc. in 1992, rebranded in 2008 to focus on medical device development. The company's core product is LuViva, a non-invasive device designed for the detection of cervical cancers and precancers. LuViva employs optical scanning technology to analyze reflected and fluorescent light from the cervix, providing a point-of-care diagnostic tool. The company aims to offer a painless and non-invasive alternative to traditional methods like Pap smears and biopsies. Guided Therapeutics operates primarily in the United States, seeking to expand its market reach through strategic partnerships and regulatory approvals in other regions. The company's business model centers on the commercialization and distribution of LuViva to healthcare providers, including gynecologists and clinics. Guided Therapeutics faces competition from established diagnostic companies and alternative screening methods. The company is based in Norcross, Georgia, and is led by CEO Mark L. Faupel, who manages a small team of four employees.

What Products and Services Does GTHP Offer?

• Develops and commercializes medical devices.
• Focuses on cervical cancer detection technology.
• Offers LuViva, a non-invasive cervical scan.
• Provides point-of-care diagnostic solutions.
• Aims to improve early detection of cervical cancers and precancers.
• Utilizes optical scanning technology for cervical analysis.

How Does GTHP Make Money?

• Sells LuViva devices to healthcare providers.
• Generates revenue from device sales and related services.
• Targets gynecologists, clinics, and hospitals.
• Focuses on point-of-care diagnostics market.

What Industry Does GTHP Operate In?

Guided Therapeutics operates within the medical device industry, specifically targeting the cervical cancer screening market. This market is characterized by established screening methods like Pap smears and HPV tests, as well as emerging technologies. The competitive landscape includes companies offering alternative diagnostic solutions and established players in women's health. The global cervical cancer screening market is expected to grow, driven by increasing awareness and the need for more effective and accessible screening methods. Guided Therapeutics aims to capture a share of this market with its LuViva device, offering a point-of-care, non-invasive option.

Who Are GTHP's Key Customers?

• Gynecologists
• Women's health centers

Guided Therapeutics, Inc. (GTHP) Valuation Context

Valued at $24.1M, GTHP is classified as a micro-cap stock.

GTHP Revenue & Earnings Trend

In Q2 FY2026, GTHP generated $0 in top-line revenue. The company recorded a net loss of $604K, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, GTHP averaged $-0.01 in diluted EPS.

Company Profile

Guided Therapeutics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Peachtree Corners, US. The company is led by CEO Mark L. Faupel. GTHP has traded publicly since 2021.

Return on equity for Guided Therapeutics, Inc. stands at 66.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -7.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -18.4%, the inverse of the P/E and a quick read on earnings relative to price.

Guided Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Over the past six months, Guided Therapeutics, Inc. insiders filed 11 SEC Form 4 transactions — 4 sales and 7 purchases. On net that is roughly 1.5M shares acquired (about $0) — insiders putting money in tends to read as conviction.

GTHP Financials

GTHP Latest News

GTHP Analyst Consensus

GTHP MoonshotScore

What Investors Ask About Guided Therapeutics, Inc. (GTHP) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources